- Home
- GLRE vs LAB Comparison
GLRE vs LAB Comparison
Compare GLRE & LAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- LAB
- Stock Information
- Founded
- GLRE 2004
- LAB 1999
- Country
- GLRE Cayman Islands
- LAB United States
- Employees
- GLRE N/A
- LAB N/A
- Industry
- GLRE Property-Casualty Insurers
- LAB Biotechnology: Laboratory Analytical Instruments
- Sector
- GLRE Finance
- LAB Industrials
- Exchange
- GLRE Nasdaq
- LAB Nasdaq
- Market Cap
- GLRE 486.3M
- LAB 562.1M
- IPO Year
- GLRE 2007
- LAB 2011
- Fundamental
- Price
- GLRE $14.12
- LAB $1.77
- Analyst Decision
- GLRE
- LAB Strong Buy
- Analyst Count
- GLRE 0
- LAB 2
- Target Price
- GLRE N/A
- LAB $2.88
- AVG Volume (30 Days)
- GLRE 83.9K
- LAB 1.7M
- Earning Date
- GLRE 03-04-2025
- LAB 02-26-2025
- Dividend Yield
- GLRE N/A
- LAB N/A
- EPS Growth
- GLRE N/A
- LAB N/A
- EPS
- GLRE 2.53
- LAB N/A
- Revenue
- GLRE $702,254,000.00
- LAB $155,902,000.00
- Revenue This Year
- GLRE N/A
- LAB $62.60
- Revenue Next Year
- GLRE N/A
- LAB $9.19
- P/E Ratio
- GLRE $5.58
- LAB N/A
- Revenue Growth
- GLRE 8.96
- LAB 48.23
- 52 Week Low
- GLRE $11.01
- LAB $1.21
- 52 Week High
- GLRE $15.82
- LAB $3.04
- Technical
- Relative Strength Index (RSI)
- GLRE 51.61
- LAB 46.48
- Support Level
- GLRE $13.42
- LAB $1.67
- Resistance Level
- GLRE $14.31
- LAB $2.14
- Average True Range (ATR)
- GLRE 0.29
- LAB 0.15
- MACD
- GLRE 0.06
- LAB -0.00
- Stochastic Oscillator
- GLRE 78.65
- LAB 32.73
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed, and income from investments.
About LAB Standard BioTools Inc.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.